Most Liquid Pharmaceuticals Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1AVBP ArriVent BioPharma, Common
128.72 M
 0.13 
 3.59 
 0.47 
2ARVN Arvinas
1.27 B
 0.01 
 3.47 
 0.03 
3NMRA Neumora Therapeutics, Common
267.57 M
 0.12 
 3.76 
 0.45 
4ELTX Elicio Therapeutics
11.02 M
(0.10)
 7.61 
(0.76)
5SXTP 60 Degrees Pharmaceuticals,
2.25 M
(0.11)
 9.70 
(1.10)
6ADGM Adagio Medical Holdings,
19.18 K
(0.24)
 8.67 
(2.12)
7SLNX Solanbridge Group
13.06 K
(0.13)
 12.91 
(1.67)
8IDCN Indocan Resources
219.37
 0.00 
 0.00 
 0.00 
9TAK Takeda Pharmaceutical Co
533.53 B
 0.16 
 1.24 
 0.20 
10NVO Novo Nordisk AS
37.47 B
 0.00 
 2.38 
(0.01)
11MRK Merck Company
12.69 B
(0.08)
 1.77 
(0.15)
12BMY Bristol Myers Squibb
9.12 B
 0.15 
 2.14 
 0.31 
13SNY Sanofi ADR
6.9 B
 0.22 
 1.42 
 0.31 
14JNJ Johnson Johnson
5.37 B
 0.20 
 1.08 
 0.21 
15NVS Novartis AG ADR
4.64 B
 0.15 
 1.08 
 0.17 
16AZN AstraZeneca PLC ADR
4.52 B
 0.01 
 1.18 
 0.01 
17GSK GlaxoSmithKline PLC ADR
3.72 B
 0.09 
 1.33 
 0.12 
18ZTS Zoetis Inc
3.58 B
 0.13 
 1.46 
 0.19 
19RDY Dr Reddys Laboratories
2.93 B
 0.16 
 1.37 
 0.21 
20PFE Pfizer Inc
2.85 B
 0.12 
 1.31 
 0.16 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).